Furthermore, HLA‐I antibodies were detected in 25.0% (5/20) of patients with CBF‐AML, while only in 6.2% (7/113) of the non‐CBF‐AML patients (P = .018, Figure 2B). This evidence concerns the gene CEBPZ and acute myeloid leukemia.